PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Rilotumumab (Primary) ; Depatuxizumab; Ramucirumab; Trastuzumab
- Indications Adenocarcinoma
- Focus Therapeutic Use
- Acronyms PANGEA-IMBBP
- 05 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.